The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PCSA | -73.28% | -99.8% | -71.23% | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +169% |
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
No news articles found for Processa Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | -48.3% |
| Market Cap | $9.66M | 116.5% |
| Market Cap / Employee | $0.97M | 0.0% |
| Employees | 10 | -23.1% |
| Net Income | -$3.44M | -1.5% |
| EBITDA | -$3.49M | -1.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.31M | 118.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -206.50% | -29.5% |
| Return On Invested Capital | -281.12% | -130.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.48M | 3.4% |
| Operating Free Cash Flow | -$3.48M | 3.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.78 | 0.81 | 0.31 | 1.27 | 93.99% |
| Price to Tangible Book Value | 0.78 | 0.81 | 0.31 | 1.27 | 93.99% |
| Enterprise Value to EBITDA | -0.79 | -0.24 | 0.94 | -0.81 | 62.99% |
| Return on Equity | -354.5% | -192.7% | -212.4% | -270.7% | 27.88% |
| Total Debt | $0.07M | $0.05M | $0.03M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
